Has the Danish Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the Danish Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 11.5x which is lower than its 3-year average PE of 29.5x. The 3-year average PS ratio of 9.7x is higher than the industry's current PS ratio of 4.1x.

How does Danish Pharma compare with similar industries?

There are no additional sub-industries under this industry.

Danish (OMX) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 25 Jun 2026	DKK 1.5t	DKK 359.9b	DKK 126.9b	11.5x	11.5x	4.1x
Sat, 23 May 2026	DKK 1.4t	DKK 359.9b	DKK 126.9b	11.1x	10.9x	3.8x
Mon, 20 Apr 2026	DKK 1.2t	DKK 340.0b	DKK 106.8b	13.2x	11.6x	3.7x
Wed, 18 Mar 2026	DKK 1.2t	DKK 340.0b	DKK 106.8b	11.8x	11.1x	3.5x
Fri, 13 Feb 2026	DKK 1.4t	DKK 339.8b	DKK 106.7b	13.3x	13.6x	4.3x
Sun, 11 Jan 2026	DKK 1.8t	DKK 345.8b	DKK 108.6b	16.3x	16.5x	5.2x
Tue, 09 Dec 2025	DKK 1.4t	DKK 345.8b	DKK 108.6b	12.8x	13.1x	4.1x
Thu, 06 Nov 2025	DKK 1.4t	DKK 341.3b	DKK 115.5b	13.1x	12.3x	4.2x
Sat, 04 Oct 2025	DKK 1.8t	DKK 341.3b	DKK 115.5b	15.2x	15.4x	5.2x
Mon, 01 Sep 2025	DKK 1.7t	DKK 341.3b	DKK 115.5b	14.4x	14.5x	4.9x
Wed, 30 Jul 2025	DKK 1.6t	DKK 331.8b	DKK 108.8b	14.7x	14.9x	4.9x
Fri, 27 Jun 2025	DKK 2.0t	DKK 331.8b	DKK 108.8b	18.3x	18.3x	6x
Sun, 25 May 2025	DKK 2.0t	DKK 331.8b	DKK 108.8b	18.8x	18.8x	6.1x
Tue, 22 Apr 2025	DKK 1.9t	DKK 317.9b	DKK 104.9b	18.5x	18.4x	6.1x
Thu, 20 Mar 2025	DKK 2.5t	DKK 317.9b	DKK 104.9b	24x	23.8x	7.8x
Sat, 15 Feb 2025	DKK 2.5t	DKK 317.8b	DKK 104.9b	24.5x	24.3x	8x
Mon, 13 Jan 2025	DKK 2.9t	DKK 297.4b	DKK 98.2b	29.6x	29.3x	9.7x
Wed, 11 Dec 2024	DKK 3.5t	DKK 297.4b	DKK 98.2b	36.5x	36x	11.9x
Fri, 08 Nov 2024	DKK 3.3t	DKK 296.4b	DKK 98.0b	34.2x	33.8x	11.2x
Sun, 06 Oct 2024	DKK 3.5t	DKK 283.9b	DKK 93.2b	38.4x	37.9x	12.4x
Tue, 03 Sep 2024	DKK 4.2t	DKK 283.9b	DKK 93.2b	45.8x	45.1x	14.8x
Thu, 01 Aug 2024	DKK 4.1t	DKK 269.3b	DKK 92.2b	45.3x	44.7x	15.3x
Sat, 29 Jun 2024	DKK 4.5t	DKK 269.3b	DKK 92.2b	50x	49.1x	16.8x
Mon, 27 May 2024	DKK 4.2t	DKK 269.3b	DKK 92.2b	46.2x	45.4x	15.6x
Wed, 24 Apr 2024	DKK 4.0t	DKK 257.0b	DKK 86.4b	47.5x	46.7x	15.7x
Fri, 22 Mar 2024	DKK 4.0t	DKK 257.0b	DKK 86.4b	47.7x	46.8x	15.8x
Sun, 18 Feb 2024	DKK 3.9t	DKK 257.0b	DKK 86.4b	45.4x	44.6x	15x
Tue, 16 Jan 2024	DKK 3.3t	DKK 238.8b	DKK 78.2b	42.9x	42.1x	13.8x
Thu, 14 Dec 2023	DKK 3.0t	DKK 238.8b	DKK 78.2b	39.8x	39x	12.8x
Sat, 11 Nov 2023	DKK 3.1t	DKK 238.8b	DKK 78.1b	41x	40.2x	13.1x
Mon, 09 Oct 2023	DKK 2.9t	DKK 225.4b	DKK 70.1b	42.9x	42x	13x
Wed, 06 Sep 2023	DKK 3.0t	DKK 225.4b	DKK 70.1b	44x	43x	13.4x
Fri, 04 Aug 2023	DKK 2.5t	DKK 211.8b	DKK 63.8b	39.3x	38.4x	11.6x
Sun, 02 Jul 2023	DKK 2.5t	DKK 211.8b	DKK 63.8b	40.3x	39.4x	11.9x


DK Market	3.72%
Healthcare	7.96%
Pharma	9.10%
Pharma	9.10%

	Company	Last Price	7D	1Y	Valuation
	NOVO B Novo Nordisk	DKK 292.95	2.0% +DKK 25.2b	-38.4%	PE10.6x
	STENO Stenocare	DKK 1.10	0.5% +DKK 216.0k	107.4%	PS5.1x

Announcement • Jun 18

ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis

ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy 1 mg, the first and only needle-free adrenaline treatment for anaphylaxis for children aged 4 and older living with severe allergies in the UK – extending a class of treatment previously available only by injection. EURneffy 1 mg is now indicated in the UK for the emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in children aged 4 years and over weighing 15 kg to less than 30 kg. This approval follows the existing UK marketing authorisation for EURneffy 2 mg, previously approved by the MHRA for the emergency treatment of anaphylaxis in adults and children weighing =30 kg. This approval means more people with severe allergies, including children aged 4 years and older who weigh 15 kg to less than 30 kg, will be eligible for treatment with EURneffy, the only needle-free adrenaline-based product currently approved in the UK. EURneffy provides rapid absorption of adrenaline within minutes of administration. EURneffy has an established safety profile, based on clinical data from the EURneffy development programme involving over 700 participants. The most common adverse reactions in subjects weighing 15 kg to less than 30 kg treated with EURneffy 1 mg included: nasal congestion (19.0%), upper respiratory tract congestion (14.3%), dry throat, nasal dryness, and paraesthesia (each 9.5%). There were no clinically relevant differences in the safety between the paediatric and adult populations treated with EURneffy. EURneffy 2 mg performed as well as traditional adrenaline auto-injectors or intramuscular adrenaline across a range of real-world scenarios examining the clinical pharmacological effect including single and repeat doses, self-administration, and situations with nasal congestion from allergies. EURneffy 1 mg dose demonstrated a comparable absorption and pharmacodynamic effect in children (15-30 kg) as the 2 mg dose in children and adults above 30 kg. EURneffy is the first and only needle-free adrenaline-based product approved for the emergency treatment of anaphylaxis in adults and children. EURneffy is well absorbed through the nose and distributed quickly into body tissues, offering a portable, pocket-sized alternative to injectable forms of adrenaline for treating severe allergic reactions. EURneffy has a total shelf life of 30 months (2 mg) and 24 months (1 mg), no special storage requirements and freezing does not affect its shelf life. Upon activation, EURneffy nasal spray delivers a full, single dose of adrenaline, without the need for priming. It is recommended that two EURneffy devices are carried to treat a potentially life-threatening emergency in case a second dose is required. In the UK and European Union, EURneffy 2 mg is approved for the emergency treatment of anaphylaxis in adults and children who weigh = 30kg, and EURneffy 1 mg is approved for the emergency treatment of anaphylaxis in children aged 4 and older who weigh from 15 kg to less than 30 kg. In the United States, Japan, China, Australia and Canada EURneffy 2 mg is approved under the brand name neffy 2 mg. In the US and Australia, neffy 1 mg has also been approved for children who weigh 15–30 kg (with an age restriction of 4 years and older in Australia) and in Japan, neffy 1 mg and 2 mg are approved for the emergency treatment of severe allergic reactions (anaphylaxis) in adults and children who weigh =15 kg.

Danish (OMX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

UK Clears Wegovy Oral Pill in Europe’s First Daily GLP-1 Weight-Loss Approval

H. Lundbeck A/S Announces Executive Changes

ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis

First quarter 2026 earnings released

Pharma Equity Group A/S announced that it expects to receive DKK 9.632073 million in funding